Drug intelligence / Profile preview

Photodithazine

Development stage
Phase 2
Lead developer
Veta-Grand
Modality
Small Molecules
Administration
Topical, Intravenous
01

Overview

Photodithazine is a second-generation photosensitizer derived from chlorin e6, specifically formulated as a bis-N-methylglucamine salt to enhance water solubility and bioavailability. Developed primarily for use in photodynamic therapy (PDT) and antimicrobial photodynamic therapy (aPDT), it exhibits a high absorption peak in the red spectrum at approximately 660 nm. Upon activation by light of this wavelength, Photodithazine undergoes a transition to an excited state, transferring energy to molecular oxygen to generate cytotoxic reactive oxygen species (ROS), such as singlet oxygen. These ROS cause localized oxidative damage, leading to the destruction of neoplastic cells, bacteria, and fungi via necrosis or apoptosis. It is utilized clinically for various oncological conditions, gynecological disorders like vulvar lichen sclerosus, and inflammatory skin conditions such as acne, and is extensively researched for its efficacy against multidrug-resistant biofilms.

Brand names
PhotodithazinePhotodithazin
Other names
Chlorin e6 glucosamine saltBis-N-methylglucamine salt of chlorin e6Photodithazinum
02

Targets

^1O2 (Singlet oxygen)

Beyond the preview

Go deeper on Photodithazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Photodithazine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call